Nicox S.A. (EPA:ALCOX)

Market Cap	28.33M -7.1%
Revenue (ttm)	16.77M +113.4%
Net Income	-2.41M
EPS	-0.03
Shares Out	88.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	280,187
Open	0.3200
Previous Close	0.3250
Day's Range	0.3180 - 0.3270
52-Week Range	0.2810 - 0.5690
Beta	0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 7, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCOX

Financial Performance

In 2025, Nicox's revenue was 16.77 million, an increase of 113.41% compared to the previous year's 7.86 million. Losses were -2.41 million, -89.22% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error